Used as a key intermediate in the synthesis of potent kinase inhibitors, particularly in the development of anticancer agents targeting EGFR (epidermal growth factor receptor) mutations. Its structural features enable selective binding to mutant forms of EGFR, making it valuable in the design of targeted therapies for non-small cell lung cancer (NSCLC). The compound's chiral center and functional groups allow for optimized pharmacokinetic properties, including improved metabolic stability and blood-brain barrier penetration, which are critical for effective central nervous system activity in treating brain metastases. It is primarily employed in research and preclinical drug development to construct more complex drug candidates with enhanced potency and selectivity.